201 related articles for article (PubMed ID: 33318034)
21. Small-cell lung cancer brain metastasis: From molecular mechanisms to diagnosis and treatment.
Zhu Y; Cui Y; Zheng X; Zhao Y; Sun G
Biochim Biophys Acta Mol Basis Dis; 2022 Dec; 1868(12):166557. PubMed ID: 36162624
[TBL] [Abstract][Full Text] [Related]
22. Survival of Black and White Patients With Stage IV Small Cell Lung Cancer.
Shi H; Zhou K; Cochuyt J; Hodge D; Qin H; Manochakian R; Zhao Y; Ailawadhi S; Adjei AA; Lou Y
Front Oncol; 2021; 11():773958. PubMed ID: 34956892
[TBL] [Abstract][Full Text] [Related]
23. Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.
Gadgeel SM
Curr Treat Options Oncol; 2018 Sep; 19(11):53. PubMed ID: 30203184
[TBL] [Abstract][Full Text] [Related]
24. Novel strategies for the treatment of small-cell lung carcinoma.
William WN; Glisson BS
Nat Rev Clin Oncol; 2011 Jun; 8(10):611-9. PubMed ID: 21691321
[TBL] [Abstract][Full Text] [Related]
25. NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model.
Liu Y; Li Y; Liu S; Adeegbe DO; Christensen CL; Quinn MM; Dries R; Han S; Buczkowski K; Wang X; Chen T; Gao P; Zhang H; Li F; Hammerman PS; Bradner JE; Quayle SN; Wong KK
Cancer Res; 2018 Jul; 78(13):3709-3717. PubMed ID: 29760044
[TBL] [Abstract][Full Text] [Related]
26. Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer.
Mak DWS; Li S; Minchom A
Eur J Cancer; 2019 Sep; 119():132-150. PubMed ID: 31445197
[TBL] [Abstract][Full Text] [Related]
27. Novel Mouse Cell Lines and In Vivo Models for Human High-Grade Neuroendocrine Lung Carcinoma, Small Cell Lung Carcinoma (SCLC), and Large Cell Neuroendocrine Carcinoma (LCNEC).
Recuero E; Lázaro S; Lorz C; Enguita AB; Garcia-Escudero R; Santos M
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894963
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC.
Potter DS; Galvin M; Brown S; Lallo A; Hodgkinson CL; Blackhall F; Morrow CJ; Dive C
Mol Cancer Ther; 2016 Jun; 15(6):1248-60. PubMed ID: 27197306
[TBL] [Abstract][Full Text] [Related]
29. Surgery for limited-stage small-cell lung cancer.
Barnes H; See K; Barnett S; Manser R
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011917. PubMed ID: 28429473
[TBL] [Abstract][Full Text] [Related]
30. Real-world effectiveness and tolerability of small-cell lung cancer (SCLC) treatments: A systematic literature review (SLR).
Povsic M; Enstone A; Wyn R; Kornalska K; Penrod JR; Yuan Y
PLoS One; 2019; 14(7):e0219622. PubMed ID: 31318909
[TBL] [Abstract][Full Text] [Related]
31. Small cell lung cancer: Subtypes and therapeutic implications.
Wang WZ; Shulman A; Amann JM; Carbone DP; Tsichlis PN
Semin Cancer Biol; 2022 Nov; 86(Pt 2):543-554. PubMed ID: 35398266
[TBL] [Abstract][Full Text] [Related]
32. DLL3: an emerging target in small cell lung cancer.
Owen DH; Giffin MJ; Bailis JM; Smit MD; Carbone DP; He K
J Hematol Oncol; 2019 Jun; 12(1):61. PubMed ID: 31215500
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges.
Pavan A; Attili I; Pasello G; Guarneri V; Conte PF; Bonanno L
J Immunother Cancer; 2019 Aug; 7(1):205. PubMed ID: 31383005
[TBL] [Abstract][Full Text] [Related]
34. Second-line treatments of small-cell lung cancers.
Baize N; Monnet I; Greillier L; Quere G; Kerjouan M; Janicot H; Vergnenegre A; Auliac JB; Chouaid C
Expert Rev Anticancer Ther; 2017 Nov; 17(11):1033-1043. PubMed ID: 28849951
[TBL] [Abstract][Full Text] [Related]
35. Unravelling the biology of SCLC: implications for therapy.
Sabari JK; Lok BH; Laird JH; Poirier JT; Rudin CM
Nat Rev Clin Oncol; 2017 Sep; 14(9):549-561. PubMed ID: 28534531
[TBL] [Abstract][Full Text] [Related]
36. Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer.
Zinn RL; Gardner EE; Dobromilskaya I; Murphy S; Marchionni L; Hann CL; Rudin CM
Mol Cancer; 2013 Mar; 12():16. PubMed ID: 23452820
[TBL] [Abstract][Full Text] [Related]
37. Overcoming Chemotherapy Resistance in SCLC.
Herzog BH; Devarakonda S; Govindan R
J Thorac Oncol; 2021 Dec; 16(12):2002-2015. PubMed ID: 34358725
[TBL] [Abstract][Full Text] [Related]
38. Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification.
Caliman E; Fancelli S; Petroni G; Gatta Michelet MR; Cosso F; Ottanelli C; Mazzoni F; Voltolini L; Pillozzi S; Antonuzzo L
Lung Cancer; 2023 Jan; 175():88-100. PubMed ID: 36493578
[TBL] [Abstract][Full Text] [Related]
39. The impact of angiogenesis inhibitors on survival of patients with small cell lung cancer.
Shi X; Dong X; Young S; Chen AM; Liu X; Zheng Z; Huang K; Lu D; Feng S; Morahan G; Cai K
Cancer Med; 2019 Oct; 8(13):5930-5938. PubMed ID: 31433125
[TBL] [Abstract][Full Text] [Related]
40. Optimal drugs for second-line treatment of patients with small-cell lung cancer.
Rossi A; Sacco PC; Sgambato A; Casaluce F; Santabarbara G; Palazzolo G; Maione P; Gridelli C
Expert Opin Pharmacother; 2016; 17(7):969-76. PubMed ID: 26878692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
